These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31454420)

  • 1. Prothymosin alpha and its mimetic hexapeptide improve delayed tissue plasminogen activator-induced brain damage following cerebral ischemia.
    Halder SK; Matsunaga H; Ueda H
    J Neurochem; 2020 Jun; 153(6):772-789. PubMed ID: 31454420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial actions of prothymosin alpha-mimetic hexapeptide on central post-stroke pain, reduced social activity, learning-deficit and depression following cerebral ischemia in mice.
    Sasaki K; Halder SK; Matsunaga H; Ueda H
    Peptides; 2020 Apr; 126():170265. PubMed ID: 31982448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prothymosin α-derived hexapeptide prevents the brain damage and sequelae due to ischemia-hemorrhage.
    Ueda H
    Peptides; 2023 Feb; 160():170922. PubMed ID: 36496010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prothymosinα, as a neuroprotective DAMPs/Alarmins molecule].
    Ueda H; Maeda S
    Nihon Yakurigaku Zasshi; 2018; 151(1):15-19. PubMed ID: 29321391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective DAMPs member prothymosin alpha has additional beneficial actions against cerebral ischemia-induced vascular damages.
    Maeda S; Sasaki K; Halder SK; Fujita W; Ueda H
    J Pharmacol Sci; 2016 Sep; 132(1):100-104. PubMed ID: 27543170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective impact of prothymosin alpha-derived hexapeptide against retinal ischemia-reperfusion.
    Ueda H; Halder SK; Matsunaga H; Sasaki K; Maeda S
    Neuroscience; 2016 Mar; 318():206-18. PubMed ID: 26779836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia.
    Liang J; Qi Z; Liu W; Wang P; Shi W; Dong W; Ji X; Luo Y; Liu KJ
    Stroke; 2015 May; 46(5):1344-1351. PubMed ID: 25804925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel neuroprotective action of prothymosin α-derived peptide against retinal and brain ischemic damages.
    Halder SK; Matsunaga H; Yamaguchi H; Ueda H
    J Neurochem; 2013 Jun; 125(5):713-23. PubMed ID: 23278181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prothymosin-alpha preconditioning activates TLR4-TRIF signaling to induce protection of ischemic retina.
    Halder SK; Matsunaga H; Ishii KJ; Ueda H
    J Neurochem; 2015 Dec; 135(6):1161-77. PubMed ID: 26364961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A broad-spectrum matrix metalloproteinase inhibitor prevents hemorrhagic complications induced by tissue plasminogen activator in mice.
    Mishiro K; Ishiguro M; Suzuki Y; Tsuruma K; Shimazawa M; Hara H
    Neuroscience; 2012 Mar; 205():39-48. PubMed ID: 22244977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication.
    Nakano T; Irie K; Hayakawa K; Sano K; Nakamura Y; Tanaka M; Yamashita Y; Satho T; Fujioka M; Muroi C; Matsuo K; Ishikura H; Futagami K; Mishima K
    Brain Res; 2015 Oct; 1624():330-335. PubMed ID: 26254727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAD replenishment with nicotinamide mononucleotide protects blood-brain barrier integrity and attenuates delayed tissue plasminogen activator-induced haemorrhagic transformation after cerebral ischaemia.
    Wei CC; Kong YY; Hua X; Li GQ; Zheng SL; Cheng MH; Wang P; Miao CY
    Br J Pharmacol; 2017 Nov; 174(21):3823-3836. PubMed ID: 28812311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole body hypothermia extends tissue plasminogen activator treatment window in the rat model of embolic stroke.
    Hassanipour M; Zarisfi M; Ehsani V; Allahtavakoli M
    Life Sci; 2020 Sep; 256():117450. PubMed ID: 32087233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-Like Receptor 4 Mediates Hemorrhagic Transformation After Delayed Tissue Plasminogen Activator Administration in In Situ Thromboembolic Stroke.
    García-Culebras A; Palma-Tortosa S; Moraga A; García-Yébenes I; Durán-Laforet V; Cuartero MI; de la Parra J; Barrios-Muñoz AL; Díaz-Guzmán J; Pradillo JM; Moro MA; Lizasoain I
    Stroke; 2017 Jun; 48(6):1695-1699. PubMed ID: 28428349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.
    Li Y; Zhu ZY; Lu BW; Huang TT; Zhang YM; Zhou NY; Xuan W; Chen ZA; Wen DX; Yu WF; Li PY
    CNS Neurosci Ther; 2019 Dec; 25(12):1343-1352. PubMed ID: 31756041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoflurane preconditioning inhibits the effects of tissue-type plasminogen activator on brain endothelial cell in an
    Cheon SY; Kim SY; Kam EH; Lee JH; Kim JM; Kim EJ; Kim TW; Koo BN
    Int J Med Sci; 2017; 14(5):425-433. PubMed ID: 28539818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phthalide derivative CD21 attenuates tissue plasminogen activator-induced hemorrhagic transformation in ischemic stroke by enhancing macrophage scavenger receptor 1-mediated DAMP (peroxiredoxin 1) clearance.
    Liu DL; Hong Z; Li JY; Yang YX; Chen C; Du JR
    J Neuroinflammation; 2021 Jun; 18(1):143. PubMed ID: 34162400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in Acute Expression of Matrix Metalloproteinases-9, 3, and 2 Related to the Duration of Brain Ischemia and Tissue Plasminogen Activator Treatment in Experimental Stroke.
    Wang D; Saleem S; Sullivan RD; Zhao T; Reed GL
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
    Liu H; Wang Y; Xiao Y; Hua Z; Cheng J; Jia J
    Transl Stroke Res; 2016 Jun; 7(3):209-19. PubMed ID: 27018013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effect of anti-HMGB1 antibody in a mouse model of 4-h middle cerebral artery occlusion: comparison with tissue plasminogen activator.
    Nakano T; Tagashira Y; Egashira S; Morimoto M; Irie K; Hosokawa M; Hayashi T; Egawa T; Hayakawa K; Mishima K
    Neuroreport; 2022 May; 33(7):297-303. PubMed ID: 35594440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.